P1: PSB Printer: Yet To Come
9780521704632ind CUFX213A/Peck 9780521618168 December 29, 2007 17:19
374 Indexparoxetine, 276
partial pressure,
inhaled anaesthetics, 114 , 116
passive diffusion,1–3
molecular size, 5
patient factors, bioavailability influence, 9
penicillins, 311 –315
allergy, 313
anti-pseudomonal, 314 –315
blood–brain barrier crossing, 15
encephalopathy, 313
extended spectrum, 314
kinetics, 313
mechanism of action, 312 –313
narrow spectrum, 314
side-effects, 313
pentazocine, 149
peroxisome proliferator-activated receptor-γ,
31 , 350–351
perphenazine, 285
pethidine, 16 , 144–145
kinetics, 144 –145
monoamine oxidase inhibitors interactions,
144
uses, 144
pharmaceutical interactions, 40
pharmaceutical preparation, bioavailability
influence, 9
pharmacodynamic drug interactions,
42 –44
direct, 42
indirect, 42
pharmacokinetic(s), 50
applied, 80 –81
pharmacokinetic drug interactions, 40 –42
bioavailability influence,9–10
non-linear kinetics, 78 –79
pharmacokinetic models, 63 –64
pharmacokinetic parameters, 72 –75
phenanthrene, 96
phencyclidine, 96 , 102–103
phenelzine, 277
phenobarbitone, 281
phenothiazines, 283 –285
groups,284t
phenoxybenzamine, 38 , 218–219
effects, 219
kinetics, 219
mechanism of action, 219
presentation, 218
uses, 218 –219
phentolamine, 217
phenyl group, 96
phenylalanine, 86
phenylbutazone, 157 –158phenylephrine, 205 –207
effects, 207
kinetics, 207
presentation, 205
uses, 205
phenytoin, 41 , 279
digoxin toxicity treatment, 245
drug interactions, 279
effects, 279
kinetics, 279
mechanism of action, 279
metabolism, 79
uses, 279
phosphodiesterase(s) (PDEs), 28
phosphodiesterase inhibitors,213f
non-selective, 212 –214
selective, 214 –216
phospholipase A 2 , 353–354
phospholipase C, 28 –30
phospholipid membrane, local anaesthetics
crossing, 165 –166
physicochemical interactions, bioavailability
influence, 9
physostigmine, 193 –195
pinocytosis,4, 5f
pioglitazone, 350 –351
piperacillin, 314 –315
piperazine, 96
piperidine, 97
pirenzipine, 295
placental blood flow, 15
placental membrane, 15
plasma, drugs confined to, 14
platelets, 335 –336
NSAID effects on function,
151 –152
phosphodiesterase inhibition, 337
unfractionated heparin mechanism of
action, 340
pneumonic plague, 320 –321
polyenes,328t, 332
polypharmacy, elderly people, 23
porphyric crises, acute
etomidate-induced,112t, 113t
thiopentone-induced, 105 –106
postoperative nausea and vomiting (PONV )
seeantiemetics; nausea; vomiting
post-synaptic membrane, 175
post-tetanic potentiation and count,
178 –179
potassium
suxamethonium effects, 181
see alsohyperkalaemia; hypokalaemia,
thiazides with digoxin
potassium channel activators, 251 –252